Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Henriette Golcher

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3362-7857; OpenAlex author ID A5046450467. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 7

  1. Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomi… Co-author DOI 10.1200/jco-25-03004↗
  2. Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO… Co-author DOI 10.1200/jco-24-01502↗
  3. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Syst… Co-author DOI 10.1001/jamaoncol.2022.0168↗
  4. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-… Co-author DOI 10.1007/s00066-020-01680-2↗
  5. Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials. First author DOI 10.1097/sla.0000000000005126↗
  6. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial. Last author DOI 10.1186/s12885-019-6148-5↗
  7. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospe… Co-author DOI 10.1007/s00066-014-0737-7↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert Grützmann · 5 shared papers, 2019–2026 · strength 0.67
  2. Michael B. Ghadimi · 4 shared papers, 2019–2026 · strength 0.58
  3. Dorota Łubgan · 4 shared papers, 2019–2026 · strength 0.58
  4. Waldemar H. Uhl · 4 shared papers, 2019–2026 · strength 0.58
  5. Anke Reinacher‐Schick · 4 shared papers, 2019–2026 · strength 0.58
  6. Helmut Oettle · 4 shared papers, 2019–2026 · strength 0.58
  7. Uwe A. Wittel · 4 shared papers, 2019–2026 · strength 0.58
  8. Sabine Semrau · 3 shared papers, 2021–2026 · strength 0.50
  9. Rainer Fietkau · 3 shared papers, 2021–2026 · strength 0.50
  10. Stefan Hubert Boeck · 3 shared papers, 2021–2026 · strength 0.50
  11. Andrea Tannapfel · 2 shared papers, 2025–2026 · strength 0.40
  12. Markus Hecht · 2 shared papers, 2025–2026 · strength 0.40
  13. Dirk Waldschmidt · 2 shared papers, 2025–2026 · strength 0.40
  14. Werner Hohenberger · 3 shared papers, 2015–2021 · strength 0.22
  15. Riccardo Casadei · 2 shared papers, 2021–2022 · strength 0.20
  16. Thomas Baptist Brunner · 2 shared papers, 2015–2021 · strength 0.14
  17. Christiane J. Bruns · 2 shared papers, 2015–2021 · strength 0.14
  18. Thierry Conroy · 1 shared paper, 2022 · strength 0.11
  19. Jean‐Luc Van Laethem · 1 shared paper, 2022 · strength 0.11
  20. Narikazu Boku · 1 shared paper, 2022 · strength 0.11
  21. Johanna W. Wilmink · 1 shared paper, 2022 · strength 0.11
  22. Paula Ghaneh · 1 shared paper, 2022 · strength 0.11
  23. Geertjan van Tienhoven · 1 shared paper, 2022 · strength 0.11
  24. Markus Wolfgang Büchler · 1 shared paper, 2022 · strength 0.11
  25. Esther N. Pijnappel · 1 shared paper, 2022 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.